Oligodendrocyte-Targeted SGK1.1 Inhibition Alleviates White Matter Injury and Cognitive Impairment in Alzheimer's Disease via Modulation of HDAC2 Phosphorylation.

IF 6.6 1区 医学 Q1 NEUROSCIENCES
Shiji Deng, Shenghan Gao, Chao Zhou, Zhen Lan, Huiya Li, Jiang Chen, Yuhao Xu, Jiashuo Li, Pinyi Liu, Siyuan Zhang, Xinyu Bao, Tingting Wang, Yun Xu, Xiaolei Zhu
{"title":"Oligodendrocyte-Targeted SGK1.1 Inhibition Alleviates White Matter Injury and Cognitive Impairment in Alzheimer's Disease via Modulation of HDAC2 Phosphorylation.","authors":"Shiji Deng, Shenghan Gao, Chao Zhou, Zhen Lan, Huiya Li, Jiang Chen, Yuhao Xu, Jiashuo Li, Pinyi Liu, Siyuan Zhang, Xinyu Bao, Tingting Wang, Yun Xu, Xiaolei Zhu","doi":"10.1002/cns.71150","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>White matter (WM) abnormalities contribute to cognitive decline in Alzheimer's disease (AD). However, the mechanisms underlying AD-associated WM vulnerability remain incompletely understood, and effective therapeutic strategies to improve WM pathology are still limited.</p><p><strong>Methods: </strong>Sgk1.1-specific RNAscope combined with Olig2 immunostaining was used to assess the cellular distribution of Sgk1.1 transcripts. Oligodendrocyte-targeted adeno-associated virus (AAV)-mediated Sgk1.1 knockdown was performed in 5 × FAD mice. Sgk1.1 overexpression was conducted in primary oligodendrocyte precursor cells (OPCs) in vitro. Phosphoproteomic profiling, co-immunoprecipitation, Phos-tag Western blot, and phospho-site mutagenesis were used to identify downstream mechanisms. A bilateral common carotid artery stenosis (BCAS) model was employed to assess broader relevance.</p><p><strong>Results: </strong>Sgk1.1 mRNA was predominantly elevated in oligodendrocyte-lineage cells of 5 × FAD mice prior to overt myelin loss. Targeted knockdown of oligodendroglial Sgk1.1 ameliorated cognitive deficits, preserved myelin ultrastructure, and promoted oligodendrocyte maturation. Conversely, Sgk1.1 overexpression arrested OPC differentiation and suppressed myelin gene expression in vitro. Mechanistically, SGK1.1 promoted HDAC2 phosphorylation at S422/S424, and blocking this phosphorylation partially reversed SGK1.1-induced maturation deficits. Furthermore, oligodendrocyte-targeted Sgk1.1 overexpression exacerbated WM injury and cognitive impairment in the BCAS model.</p><p><strong>Conclusion: </strong>Our findings identify oligodendrocyte-targeted SGK1.1 inhibition as a tractable therapeutic strategy to preserve WM integrity and cognitive function, and define HDAC2 S422/S424 phosphorylation as a mechanistic node linking SGK1.1 signaling to impaired myelination in AD and related demyelinating disorders.</p>","PeriodicalId":154,"journal":{"name":"CNS Neuroscience & Therapeutics","volume":"32 9","pages":"e71150"},"PeriodicalIF":6.6000,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13554428/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"CNS Neuroscience & Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/cns.71150","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
引用次数: 0

Abstract

Background: White matter (WM) abnormalities contribute to cognitive decline in Alzheimer's disease (AD). However, the mechanisms underlying AD-associated WM vulnerability remain incompletely understood, and effective therapeutic strategies to improve WM pathology are still limited.

Methods: Sgk1.1-specific RNAscope combined with Olig2 immunostaining was used to assess the cellular distribution of Sgk1.1 transcripts. Oligodendrocyte-targeted adeno-associated virus (AAV)-mediated Sgk1.1 knockdown was performed in 5 × FAD mice. Sgk1.1 overexpression was conducted in primary oligodendrocyte precursor cells (OPCs) in vitro. Phosphoproteomic profiling, co-immunoprecipitation, Phos-tag Western blot, and phospho-site mutagenesis were used to identify downstream mechanisms. A bilateral common carotid artery stenosis (BCAS) model was employed to assess broader relevance.

Results: Sgk1.1 mRNA was predominantly elevated in oligodendrocyte-lineage cells of 5 × FAD mice prior to overt myelin loss. Targeted knockdown of oligodendroglial Sgk1.1 ameliorated cognitive deficits, preserved myelin ultrastructure, and promoted oligodendrocyte maturation. Conversely, Sgk1.1 overexpression arrested OPC differentiation and suppressed myelin gene expression in vitro. Mechanistically, SGK1.1 promoted HDAC2 phosphorylation at S422/S424, and blocking this phosphorylation partially reversed SGK1.1-induced maturation deficits. Furthermore, oligodendrocyte-targeted Sgk1.1 overexpression exacerbated WM injury and cognitive impairment in the BCAS model.

Conclusion: Our findings identify oligodendrocyte-targeted SGK1.1 inhibition as a tractable therapeutic strategy to preserve WM integrity and cognitive function, and define HDAC2 S422/S424 phosphorylation as a mechanistic node linking SGK1.1 signaling to impaired myelination in AD and related demyelinating disorders.

少突胶质细胞靶向SGK1.1抑制通过调节HDAC2磷酸化减轻阿尔茨海默病的白质损伤和认知障碍
背景:白质(WM)异常导致阿尔茨海默病(AD)的认知能力下降。然而,ad相关WM易感性的机制仍然不完全清楚,改善WM病理的有效治疗策略仍然有限。方法:采用Sgk1.1特异性RNAscope结合Olig2免疫染色法评估Sgk1.1转录本的细胞分布。少突胶质细胞靶向腺相关病毒(AAV)介导的Sgk1.1敲低在5 × FAD小鼠中进行。Sgk1.1在体外原代少突胶质前体细胞(OPCs)中过表达。磷酸化蛋白质组学分析、共免疫沉淀、磷酸化标记Western blot和磷酸化位点诱变用于鉴定下游机制。采用双侧颈总动脉狭窄(BCAS)模型评估更广泛的相关性。结果:5 × FAD小鼠的少突胶质细胞谱系细胞中,Sgk1.1 mRNA在髓磷脂明显丧失前显著升高。靶向敲低少突胶质细胞Sgk1.1可改善认知缺陷,保留髓鞘超微结构,促进少突胶质细胞成熟。相反,Sgk1.1过表达阻止OPC分化并抑制髓磷脂基因在体外的表达。从机制上讲,SGK1.1促进了HDAC2在S422/S424位点的磷酸化,阻断该磷酸化部分逆转了SGK1.1诱导的成熟缺陷。此外,少突胶质细胞靶向Sgk1.1过表达加重了BCAS模型的WM损伤和认知功能障碍。结论:我们的研究发现,以少突胶质细胞为靶点的SGK1.1抑制是一种可控制的治疗策略,可保持WM完整性和认知功能,并确定HDAC2 S422/S424磷酸化是将SGK1.1信号与AD和相关脱髓鞘疾病的髓鞘损伤联系起来的机制节点。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CNS Neuroscience & Therapeutics
CNS Neuroscience & Therapeutics 医学-神经科学
CiteScore
7.30
自引率
12.70%
发文量
240
审稿时长
2 months
期刊介绍: CNS Neuroscience & Therapeutics provides a medium for rapid publication of original clinical, experimental, and translational research papers, timely reviews and reports of novel findings of therapeutic relevance to the central nervous system, as well as papers related to clinical pharmacology, drug development and novel methodologies for drug evaluation. The journal focuses on neurological and psychiatric diseases such as stroke, Parkinson’s disease, Alzheimer’s disease, depression, schizophrenia, epilepsy, and drug abuse.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书